• SEC Filings

(b) On August 11, 2017, Richard J. Larkin, the Chief Financial Officer and an Executive Vice President of Chembio Diagnostics, Inc. (the "Company"), informed the Company of his intention to retire from the Company. Mr. Larkin's retirement is effective on the earlier to occur of December 31, 2017 or the date on which a new CFO has been engaged and commences work for the Company. Mr. Larkin will continue his role with the Company until the effective date of his retirement.

The press release announcing Mr. Larkin's retirement is furnished as Exhibit 99.1 to this Current Report on Form 8-K.

ITEM 9.01.FINANCIAL STATEMENTS AND EXHIBITS

(d) Exhibits.

CHEMBIO DIAGNOSTICS, INC. Exhibit
EX-99.1 2 exhibit99_1.htm EXHIBIT 99.1 PRESS RELEASE Exhibit 99.1   Chembio Diagnostics Announces Retirement of Chief Financial Officer MEDFORD,…
To view the full exhibit click here

About CHEMBIO DIAGNOSTICS, INC. (NASDAQ:CEMI)

Chembio Diagnostics, Inc. (Chembio), and its subsidiary, Chembio Diagnostic Systems, Inc., develop, manufacture, market and license rapid point-of-care diagnostic tests (POCTs) that detect infectious diseases. The Company’s products available are rapid tests for the detection of human immunodeficiency virus (HIV) 1/2 antibodies, and a multiplex rapid test for the detection of HIV and Syphilis antibodies. The HIV 1/2 rapid tests employ in-licensed and lateral flow technologies that are used with all blood matrices as samples, and are manufactured in a standard cassette format, a dipstick format and a barrel format. Its HIV 1/2 rapid antibody detection test incorporates the Dual Path Platform (DPP) POCT technology. The DPP HIV 1/2 Assay detects antibodies to HIV 1 and 2 in oral fluid samples, as well as in all blood matrices. The Company’s product pipeline includes a multiplex rapid test for earlier detection of HIV and a multiplex test that detects HIV and Syphilis specific antibodies.